Paediatric drug-induced epidermal necrolysis: insights from real-world evidence in Türkiye
Clinical and Experimental Dermatology · 2025
DOI: 10.1093/ced/llaf274 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von Esra Kiratli Nalbant und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venerology, Ankara Yildirim Beyazit University, Faculty of Medicine, Ankara, Türkiye. Hauptthemen laut MEDLINE: Stevens-Johnson Syndrome, Anti-Bacterial Agents, Anticonvulsants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background
Drug-induced epidermal necrolysis is a recently proposed entity designed to clearly differentiate medication-triggered Stevens–Johnson syndrome and toxic epidermal necrolysis from infection-related and idiopathic disease, particularly in paediatric patients.
Objectives
To characterize the clinical features of paediatric drug-induced epidermal necrolysis, a condition with relatively limited data in the literature.
Methods
This retrospective study analysed the electronic medical records of paediatric patients diagnosed with Stevens–Johnson syndrome and toxic epidermal necrolysis in Türkiye between 2018 and 2024. Patient cases were identified using ICD-10 codes from a national database, and only those with a confirmed drug-related aetiology were included. Clinical characteristics, suspected causative drugs, disease severity, in-hospital complications and treatment approaches were evaluated. Statistical analyses were performed to assess differences in clinical outcomes based on drug type and disease severity.
Results
In total, 33 paediatric patients were included. Antibiotics (45%, 15/33) and antiepileptic drugs (36%, 12/33) were the most commonly implicated medications. In-hospital complications occurred in 67% of patients (22/33), with septicaemia being the most frequent. The patients with toxic epidermal necrolysis had significantly longer hospital stays. Statistical analyses revealed differences in clinical presentation and disease course based mainly on the causative drug, with patients with antiepileptic-induced cases exhibiting a later onset and fewer in-hospital complications.
Conclusions
This study highlights the distinct clinical characteristics of paediatric drug-induced epidermal necrolysis, emphasizing the impact of causative drugs on disease course and outcomes, which may aid in improving diagnosis and treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venerology, Ankara Yildirim Beyazit University, Faculty of Medicine, Ankara, Türkiye.
- Dermatology and Venerology Clinic, Ankara Bilkent City Hospital, Ankara, Türkiye.
- Pediatric Allergy and Immunology Clinic, Ankara Etlik City Hospital, Ankara, Türkiye.
- Department of Pediatric Allergy and Immunology, Ankara Yildirim Beyazit University, Faculty of Medicine, Ankara, Türkiye.
- Department of Strategy Development, Republic of Türkiye, Ministry of Health, Ankara, Türkiye.
- Ministry of Health, Ankara, Türkiye.
ORCID-Profile: Esra Kiratli Nalbant, Burcu Ozkan Kirgin, Naim Ata, Koray Harmanci, Zulfikar Akelma
Zitieren
APA
Kiratli Nalbant, E., Ozkan Kirgin, B., Sirin, S., Ata, N., Birinci, S., Harmanci, K., & Akelma, Z. (2025). Paediatric drug-induced epidermal necrolysis: insights from real-world evidence in Türkiye. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llaf274
Vancouver
Kiratli Nalbant E, Ozkan Kirgin B, Sirin S, Ata N, Birinci S, Harmanci K, et al. Paediatric drug-induced epidermal necrolysis: insights from real-world evidence in Türkiye. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llaf274
BibTeX
@article{KiratliNalbant2025,
author = {Kiratli Nalbant, Esra and Ozkan Kirgin, Burcu and Sirin, Seda and Ata, Naim and Birinci, Suayip and Harmanci, Koray and Akelma, Zulfikar},
title = {Paediatric drug-induced epidermal necrolysis: insights from real-world evidence in Türkiye},
journal = {Clinical and Experimental Dermatology},
year = {2025},
doi = {10.1093/ced/llaf274}
}
EUVIMED